| Literature DB >> 30013175 |
Jing Chen1, Marina Gálvez-Peralta2,3, Xiang Zhang2, Jingyuan Deng2,4, Zijuan Liu5, Daniel W Nebert6.
Abstract
Slc39a8 encodes ZIP8, a divalent cation/bicarbonate symporter expressed in pluripotent mouse embryonic stem cells, and therefore ubiquitous in adult tissues; ZIP8 influxes Zn2+, Mn2+ and Fe2+. Slc39a8(neo/neo) knockdown mice exhibit 10-15% of wild-type ZIP8 mRNA and protein levels, and show pleiotropic phenotype of stunted growth, neonatal lethality, multi-organ dysmorphogenesis, and dysregulated hematopoiesis manifested as severe anemia. Herein we performed RNA-seq analysis of gestational day (GD)13.5 yolk sac and placenta, and GD16.5 liver, kidney, lung, heart and cerebellum, comparing Slc39a8(neo/neo) with Slc39a8(+/+) wild-type. Meta-data analysis of differentially-expressed genes revealed 29 unique genes from all tissues - having enriched GO categories associated with hematopoiesis and hypoxia and KEGG categories of complement, response to infection, and coagulation cascade - consistent with dysregulated hematopoietic stem cell fate. Based on transcription factor (TF) profiles in the JASPAR database, and searching for TF-binding sites enriched by Pscan, we identified numerous genes encoding zinc-finger and other TFs associated with hematopoietic stem cell functions. We conclude that, in this mouse model, deficient ZIP8-mediated divalent cation transport affects zinc-finger (e.g. GATA proteins) and other TFs interacting with GATA proteins (e.g. TAL1), predominantly in yolk sac. These data strongly support the phenotype of dysmorphogenesis and anemia seen in Slc39a8(neo/neo) mice in utero.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30013175 PMCID: PMC6048144 DOI: 10.1038/s41598-018-29109-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Properties and phenotypes reported, to date, for mammalian SLC39A8 gene.
| Organ or system | Properties/Phenotypes of mammalian | References |
|---|---|---|
| Systemic | Mouse ZIP8 transports Zn2+, Mn2+, Cd2+/and probably Fe2+ and Co2+ — each presumanly as a M++/(HCO3−)2 electroneutral complex, moving ions into the cell; |
[ |
| Developmental | Mouse |
[ |
| Liver | Mouse |
[ |
| Kidney | Mouse |
[ |
| Lung | Mouse |
[ |
| Cardiovascular system | Mouse |
[ |
| Blood chemistry | Mouse |
[ |
| Hematological system | Mouse |
[ |
| Immune system | ZIP8 originally discovered in human monocytes; Human ZIP8 participates in Zn2+-mediated immune response to inflammation, participates in innate immune response to endotoxin-induced macrophage inflammation, and host response in macrophages to |
[ |
| Central nervous system | Mouse |
[ |
| Eye | Human |
[ |
| Spleen | Mouse |
[ |
| Gastrointestinal tract | Human |
[ |
| Musculoskeletal system | Mouse |
[ |
| Reproductive system | Mouse |
[ |
aThe term “trend’” denotes P-value > 0.05 < 0.10.
bALT, alanine aminotransferase (common measurement used to assess damage largely in liver); AST, aspartate aminotransferase (common measurement used to assess damage in heart, skeletal muscle, kidney and brain, as well as liver.
Figure 1Phenotype of Slc39a8(+/+), Slc39a8(+/neo), and Slc39a8(neo/neo) littermates. (A) GD16.5 pups with corresponding placentas below. Slc39a8(neo/neo) mice were remarkably abnormal – showing deformed skull and shortened limbs, as well as severe anemia, from the time during development that an embryonal sac can first be observed. (B) Newborns, postnatal day 1 – shortly before death of the Slc39a8(neo/neo) homozygote. Compared with Slc39a8(+/+) wild-type and Slc39a8(+/neo) heterozygotes that are pink in color and normal in size, the Slc39a8(neo/neo) littermates are extremely pale, show stunted growth, and deformed skulls and limbs. Slc39a8(neo/neo) liver, kidney, lung, spleen, cerebrum and cerebellum were all statistically significantly smaller in size than that in Slc39a8(+/+) or Slc39a8(+/neo) littermates[13]. For the RNA-seq analysis described herein, Slc39a8(+/neo) littermates were not studied.
Genes differentially regulated with FDR < 0.1, when comparing Slc39a8(neo/neo) with Slc39a8(+/+) wild-type.
| Gene symbol | Official gene name | Average expression (RPKM)a | Fold-Change | log2 Fold-Change |
|
|
|---|---|---|---|---|---|---|
| GD13.5 YOLK SAC | ||||||
|
b
|
| 15.1 | 19.23456 | +4.265629 | 5.00E-05 | 0.070067 |
|
| stanniocalcin 2 | 28.3 | 15.36555 | 3.941627 | 1.25E-12 | 8.15E-09 |
|
| RIKEN cDNA 2610528A11 gene | 20.3 | 14.19895 | 3.827712 | 7.79E-10 | 3.05E-06 |
|
| predicted gene 853 | 17.5 | 9.210799 | 3.203326 | 1.74E-07 | 0.000487 |
|
| insulin-like growth factor-binding protein 1 | 248.6 | 7.475471 | 2.902165 | 2.08E-14 | 4.08E-10 |
|
c
| alcohol dehydrogenase 7 (class IV), μ or σ polypeptide | 41.1 | 7.286177 | 2.865162 | 1.67E-10 | 8.20E-07 |
|
c
| zinc-finger and BTB domain-containing 8b | 22.7 | 5.996628 | 2.584151 | 2.51E-05 | 0.037875 |
|
| polycystic kidney and hepatic disease 1-like 1 | 246.1 | 4.879078 | 2.286609 | 1.09E-12 | 8.15E-09 |
|
| LanC lantibiotic synthetase component C-like 3 ( | 24.0 | 4.443403 | 2.151665 | 2.22E-05 | 0.037875 |
|
| Reelin | 63.4 | 4.442197 | 2.151274 | 7.02E-05 | 0.091747 |
|
| EGL nine homolog 3 ( | 97.8 | 4.218064 | 2.076581 | 4.61E-09 | 1.51E-05 |
|
b
|
| 56.0 | 3.825722 | +1.935732 | 5.02E-07 | 0.001095 |
|
| solute carrier family 30, member 10 | 38.1 | 3.592453 | +1.844969 | 2.38E-05 | 0.037875 |
|
| very-low-density lipoprotein receptor | 278.3 | 3.005814 | 1.587756 | 2.19E-07 | 0.000538 |
|
b
|
| 19218.6 | 0.306581 | −1.70566 | 2.09E-06 | 0.0041 |
|
| ||||||
|
b
|
| 72.1 | 18.87205 | +4.238179 | 2.15E-06 | 0.045538 |
|
b
|
| 51.3 | 5.689857 | 2.508392 | 6.52E-06 | d 0.069045 |
|
| ||||||
|
| RIKEN cDNA 6030408B16 gene | 693.3 | 0.179781 | −2.47569 | 3.07E-06 | d 0.061137 |
|
| ||||||
| NO SIGNIFICANT GENES FOUND | ||||||
|
| ||||||
|
b
|
| 569.1 | 0.256586 | −1.96249 | 5.30E-06 | 0.008782 |
|
| alpha-2-HS-glycoprotein | 68.3 | 0.241724 | −2.04857 | 6.85E-07 | 0.001512 |
|
| pregnancy-zone protein | 121.7 | 0.234948 | −2.08958 | 2.53E-06 | 0.005029 |
|
| serine (or cysteine) peptidase inhibitor, clade A, member 1C | 25.8 | 0.224163 | −2.15738 | 2.67E-05 | 0.040878 |
|
b
|
| 125.3 | 0.210643 | −2.24712 | 1.10E-08 | 5.47E-05 |
|
| serine (or cysteine) preptidase inhibitor, clade A, member 1B | 40.9 | 0.210225 | −2.24999 | 4.19E-07 | 0.001042 |
|
| transthyretin | 61.2 | 0.209949 | −2.25189 | 8.56E-08 | 0.000272 |
|
b
|
| 41.5 | 0.196759 | −2.34550 | 9.57E-08 | 0.000272 |
|
b
|
| 96.2 | 0.195113 | −2.35762 | 1.06E-10 | 2.11E-06 |
|
b
|
| 90.3 | 0.191209 | −2.38678 | 3.55E-10 | 3.53E-06 |
|
| serine (or cysteine) peptidase inhibitor, clade A, member 6 | 72.8 | 0.170657 | −2.55083 | 4.07E-09 | 2.70E-05 |
|
b
| α1-microglobulin/bikunin | 15.3 | 0.088155 | −3.50381 | 3.98E-06 | 0.007188 |
|
| inter-α trypsin inhibitor, heavy chain 3 | 25.2 | 0.084581 | −3.56353 | 2.61E-08 | 0.000104 |
|
| ||||||
| NO SIGNIFICANT GENES FOUND | ||||||
|
| ||||||
| NO SIGNIFICANT GENES FOUND | ||||||
aRPKM, “number of Reads-Per-Kilobase-of-transcript-per-Million mapped reads”.
bGenes that are erythropoiesis- and hypoxia-related – including those involved in iron transport; these also include all platelet and white-cell types and functions because all are derived from hematopoietic stem cells.
cThese two genes encode Zn2+-containing proteins. ADH7 is an enzyme, and ZBTB8B is a Zn2+-finger TF.
dAlthough 31 genes are listed, these two are not statistically significant (i.e. P > 0.05 when Padj is taken into account).
Figure 2Characterization of Slc39a8(+/+) wild-type vs Slc39a8(neo/neo) mRNA expression levels in the seven tissues studied. Expression levels are indicated by RPKM, or “number of eads-er-ilobase-of-transcript-per-illion mapped reads.” This analysis takes into account the number of reads, normalized to size of the library, and transcriptional length of each gene. In all tissues, expression levels in Slc39a8(neo/neo) samples were lower than those in Slc39a8(+/+) wild-type. Bars represent average mean values of three determinations, and brackets denote S.E.M.
Figure 3Heat maps plotting log2 fold-changes (FC) in differential expression. Using a cut-off of P < 0.05, and requiring absolute fold-change of >2.0, the Slc39a8 gene is also included. (A) Differentially-expressed genes in at least three tissues. (B) Differentially-expressed genes in at least two tissues. Two hemoglobin genes were significantly differentially down-regulated in all tissues except liver.
Figure 4Heat maps, plotting log2 fold-changes (FC). A FDR-adjusted meta-P-value of <0.1 was used. (A) Forty-five differentially-expressed genes that are consistently down-regulated in all tissues. (B) The two differentially-expressed genes that are consistently up-regulated in all tissues.
Significant transcription factor (TF)-binding sites in genes having differential-expression at P < 0.05 and absolute fold-change >2; TF-binding site enrichment by Pscana.
| TF Nameb | Matrix ID | Z Score | Bonferroni | |
|---|---|---|---|---|
|
| ||||
|
| MA0163.1 | 5.12465 | 1.42E-07 | 9.00E-05 |
|
| MA0259.1 | 5.09355 | 1.67E-07 | 0.000105754 |
|
| MA0116.1 | 4.17542 | 1.43E-05 | 0.009050338 |
|
| MA0657.1 | 4.16993 | 1.45E-05 | 0.009184069 |
|
| MA0079.3 | 4.04080 | 2.60E-05 | 0.016508603 |
|
| MA0737.1 | 3.69324 | 0.000107782 | 0.06844157c |
|
| ||||
|
| MA0482.1 | 4.80921 | 7.39E-07 | 0.000469005 |
|
| MA0035.3 | 4.57615 | 2.31E-06 | 0.001464596 |
|
| MA0035.2 | 4.12192 | 1.84E-05 | 0.011684635 |
|
| MA0036.2 | 3.84142 | 5.99E-05 | 0.03805663 |
|
| ||||
|
| MA0508.1 | 3.81093 | 6.77507E-05 | 0.04302169 |
|
| ||||
|
| MA0114.2 | 5.94132 | 1.30E-09 | 8.25E-07 |
|
| MA0484.1 | 5.47657 | 2.01E-08 | 1.28E-05 |
|
| MA0047.1 | 5.37203 | 3.64E-08 | 2.31E-05 |
|
| MA0114.3 | 5.29283 | 5.63E-08 | 3.57E-05 |
|
| MA0153.1 | 5.20468 | 9.09E-08 | 5.77E-05 |
|
| MA0046.1 | 4.93196 | 3.75E-07 | 0.000238357 |
|
| MA0148.1 | 4.85155 | 5.82E-07 | 0.000369529 |
|
| MA0148.2 | 4.83018 | 6.48E-07 | 0.000411578 |
|
| MA0153.2 | 4.7235 | 1.09E-06 | 0.000694766 |
|
| MA0114.1 | 4.64095 | 1.64E-06 | 0.001038854 |
|
| MA0046.2 | 4.51127 | 3.06E-06 | 0.00194136 |
|
| MA0754.1 | 4.01251 | 2.88E-05 | 0.018313464 |
|
| MA0755.1 | 3.9537 | 3.70E-05 | 0.02347703 |
|
| MA0047.2 | 3.85396 | 5.64E-05 | 0.035813048 |
|
| MA0148.3 | 3.72288 | 9.58E-05 | 0.060801885c |
|
| MA0837.1 | 3.677 | 0.00011437 | 0.072621775c |
|
| MA0607.1 | 3.60496 | 0.00015141 | 0.09614281c |
|
| MA0856.1 | 3.60157 | 0.00015358 | 0.097521395c |
|
| ||||
|
| MA0154.2 | 3.90828 | 4.56688E-05 | 0.02899969 |
aUsing this rigorous method of analysis, we found no significant TF-binding sites in placenta, liver or cerebellum.
bTF name denotes the TF-binding site(s) enriched by Pscan.
cAlthough 30 enriched TF-binding sites are listed, these five are not statistically significant (i.e. P > 0.05 when the Bonferroni-corrected P-value is taken into account).
Figure 5Illustration of critically affected genes and their downstream effects that most closely fit the data presented in the present study. ZIP8 deficiency (top), has a major impact on TAL1 and GATA transcription factors (TFs), which appear to function primarily in the hematopoietic stem cells of Slc39a8(neo/neo) GD13.5 yolk sac. This function then causes severe dysregulation of hematopoietic stem cell fate and striking anemia in yolk sac, which is visibly obvious [in Fig. S2 of ref.[13]]. Moreover, hematopoiesis in yolk sac is well known to precede that in liver and then spleen and marrow [cf. Fig. S4 of ref.[13]]. Downstream effects, as development proceeds, include severe anemia and defects in coagulation, innate immunity, and response to inflammation. The striking anemia leads to a hypoxia response which is seen in all tissues examined, but largely in yolk sac. TAL1, T-cell acute lymphocytic leukemia protein-1 TF. GATA, family of six zinc-finger TFs that regulate hematopoietic stem cell fate. Interactions between TAL1 and GATA exist[61] [see text]. ZIP8-deficiency, plus the result of all these downstream changes, alter the expression of nine Cyp genes and 27 Slc genes (excluding Slc39a8); these changes are mostly unique to one tissue, as detailed in Supplementary Table S1. Δ denotes “changes in”. HIF, hypoxia-inducible factor.